MedPath

Does giving higher dose of folic acid improve intolerance associated with methotrexate in patients of Rheumatoid arthritis

Phase 4
Conditions
Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified
Registration Number
CTRI/2023/04/051346
Lead Sponsor
PGIMER, Chandigarh
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Age between 18 and 75 years

2. Diagnosis of RA made as per ACR EULAR 2010 criteria

3. Currently receiving methotrexate for more than 3 months

4. Methotrexate Intolerance Severity Assessment Score >4 qualifying as methotrexate intolerance

Exclusion Criteria

Unable to follow up at 16 weeks

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in primary intolerances at 16 weeks by MISA scoreTimepoint: Change in primary intolerances at 16 weeks by MISA score
Secondary Outcome Measures
NameTimeMethod
Change in DAS 28 3 variable score at 16 weeksTimepoint: 16 weeks;Change in RBC/Serum folate at the end of 16 weeksTimepoint: 16 weeks
© Copyright 2025. All Rights Reserved by MedPath